PBS covers FDA peptide supplement meeting, oral Wegovy approved on OASIS 4 data, and The Guardian editorial slams RFK Jr.'s peptide deregulation.
10 stories · Covering regulatory, industry, clinical-trials
The FDA's public meeting on peptides as dietary supplements continues to dominate — PBS NewsHour and the AP provided extensive coverage of the first such meeting under RFK Jr.'s HHS leadership. The Guardian editorial board published a sharp rebuke, calling the deregulation push a gift to "hucksters." Meanwhile, oral Wegovy secured FDA approval following positive OASIS 4 trial results, and the AP published a major investigation into the growing trend of influencer-promoted unapproved peptide injections.
The FDA held a public meeting at the Natural Products Association's request to discuss broadening supplement criteria to include peptides. FDA official Kyle Diamantas emphasized 'cutting red tape' under the Kennedy-era HHS stance.
The Guardian editorial board criticizes RFK Jr.'s plan to open up ~14 injectable peptides, arguing the MAHA agenda replaces the precautionary principle with 'do your own research' rhetoric benefiting wellness profiteers.
FDA approved oral Wegovy (semaglutide) based on OASIS 4 trial showing significant improvements in glycemic control and cardiovascular risk factors. Novo Nordisk plans full US launch from North Carolina manufacturing.
In-depth AP investigation on influencers and celebrities promoting unapproved injectable peptides produced by compounding pharmacies without FDA-level scrutiny.
AJMC covers the oral GLP-1 era: participants on 25mg oral semaglutide saw ~16.6% weight loss when adherent, comparable to injectable outcomes. Discusses broader market implications.
Analyzes the announcement that ~14 of 19 peptides on FDA's Category 2 list will move back to Category 1, restoring access through licensed compounding pharmacies with a prescription.
Pharmacy Times covers orforglipron's ability to cut A1C and drive meaningful weight loss with easier dosing than injections, potentially reshaping the GLP-1 treatment landscape.
Pharmacist guide on new self-pay pricing for tirzepatide, navigating insurance and medication switching, with warnings against unsafe compounded GLP-1 products.
APC CEO Scott Brunner discusses the regulatory landscape for compounded GLP-1 receptor agonists amid increasing scrutiny and legal battles over compounded peptide drugs.
Following Novo Nordisk's patent expiry on March 20, more than 50 generic semaglutide versions are anticipated in India, dramatically expanding GLP-1 access.